&w=3840&q=100)
Drugmakers may lose product licence if govt labs flag quality failures
Rimjhim Singh New Delhi
The Ministry of Health is planning strict action against pharmaceutical companies if their medicines fail quality checks. The ministry is in talks with state authorities to allow immediate suspension of licences for drugs found to be 'Not of Standard Quality' (NSQ) by government laboratories, according to a report by The Economic Times.
This move aims to ensure consistent drug quality and safeguard public health, especially after several cases of substandard medicines were reported across the country.
Recommendation of drug advisory board
The proposed action follows the recommendation of the Drugs Technical Advisory Board (DTAB), the apex body advising the Central Drugs Standard Control Organisation (CDSCO). The board, in its recent meeting, underlined the need for quick regulatory intervention once a drug is declared NSQ, the news report said.
'The board noted that it is very important that once a drug is declared NSQ, the license of such product shall be suspended immediately in public interest unless a satisfactory corrective action and preventive action (CAPA) is submitted by such manufactures. After detailed deliberation, DTAB recommended the appropriate amendment in the Drug Rules in this regard and the suspension product licence should be revoked only after root cause analysis and corresponding CAPA has been implemented,' said the minutes of the meeting.
The CDSCO is currently holding discussions with pharmaceutical industry associations, many of which have raised objections to the proposed rule.
'The health ministry and the CDSCO is taking a step forward by taking views of the states and pharma bodies as it would require a notification,' said a senior government official, as quoted by The Economic Times.
Pharma industry voices concerns
Pharmaceutical industry representatives argue that NSQ declarations can stem from technical issues rather than deliberate negligence. The Federation of Pharma Entrepreneurs (FOPE) noted in its submission, 'NSQ is a global phenomenon, and most of the time, it is due to technical issues without any wrongful intent.'
Industry groups also highlighted potential shortcomings in government laboratory practices. 'This has been a long-standing concern. It is also necessary that the NSQ investigation includes a review of records and data from government testing laboratories, as well as GLP compliance by the Drugs Inspector,' said a member of one such lobby group, as quoted by The Economic Times.
Industry demands robust review and recall mechanisms
Drugmakers emphasise that rather than immediately suspending licences, the focus should be on strengthening the drug recall mechanism and conducting thorough investigations before action is taken.
FOPE has also called for a detailed impact assessment of the proposed rules. 'We fear it may lead to malpractices in the profession, and genuine manufacturers with investments of hundreds of crores in plant setup, product development, technical team development, brand development, business development, and goodwill, may be adversely impacted if actions like the suspension of product permission are taken without proper investigation,' the group said.
Novo Nordisk launches Wegovy in India
Danish drugmaker Novo Nordisk on Tuesday launched its weight-loss injection Wegovy in India. The once-a-week injectable, already available in the US and Europe, will reach Indian pharmacies by the end of June. Wegovy contains semaglutide, a compound that mimics a natural hormone to help control appetite, reduce cravings, and promote fullness — making it easier for users to adopt healthier habits. Approved for long-term weight management, it also lowers heart-related risks in overweight or obese individuals.
Clinical trials suggest that around one in three users may lose up to 20 per cent of their body weight in just over a year, when combined with diet and exercise. In India, Wegovy is recommended for adults with a BMI of 30 or above, or over 27 with health issues like diabetes or high blood pressure. It is administered once weekly with a pre-filled pen, and the dose increases gradually. Monthly prices range from ₹17,345 to ₹26,015 depending on the dosage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Chemists urge crackdown on instant online delivery of high-risk medicines
India's leading chemists' association has warned that e-pharmacies and quick commerce platforms are delivering high-risk prescription drugs without adequate oversight — a practice, it says, could drive drug abuse and endanger public health, according to a report in The Economic Times. Why it matters The All India Organisation of Chemists and Druggists (AIOCD) said that this 'unchecked' online supply undermines drug regulations, fuels substance misuse among youth, and threatens small pharmacy businesses. • In an August 11 letter to Union Home Minister Amit Shah, AIOCD accused platforms like Zepto and Blinkit of delivering Schedule H, H1, and X drugs within minutes, skipping mandatory prescription verification. • The group flagged 'ghost prescriptions', where medicines are approved without genuine verification — including late-night approvals for distant patients. • It warned that easy online access to habit-forming drugs like Pregabalin could cause a spike in misuse. 'Foreign-funded start-ups are treating medicines like ordinary commodities, undermining India's domestic market and causing unemployment,' AIOCD wrote. The Economic Times report quoted AIOCD President JS Shinde and General Secretary Rajiv Singhal emphasising that offline chemists face strict rules, while 'illegal online players' remain unchecked — contributing to a 55 per cent surge in drug abuse. They also alleged misuse of telemedicine guidelines to bypass safeguards. Drug price monitoring Last month, the National Pharmaceutical Pricing Authority (NPPA) told drugmakers that it will closely watch price hikes for medicines outside the National List of Essential Medicines (NLEM). • Non-scheduled drugs can only see a 10 per cent price increase in a 12-month period. • Any increase above that will require repayment of the overcharged amount with interest and penalties. • NPPA has also directed that the same drug sold under multiple brands must have an MRP difference of no more than 10 per cent. What's next in prescription protocols? If the government acts on AIOCD's request, quick commerce players could face stricter prescription verification rules and limits on the delivery of high-risk medicines.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Ozempic, other weight-loss drugs tied to rare, serious eye issue: Study
Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world. Collectively known as GLP-1 agonists, these drugs mimic the hormone GLP-1. This limits both hunger and interest in food, helping users lose weight, and helps control blood sugar levels. But two new studies published today show that people taking these drugs may have a small increased risk of serious eye conditions and vision loss. Here's what you need to know if you're taking or considering these medications. What damage can occur? Non-arteritic anterior ischaemic optic neuropathy, or NAION, is a rare but devastating eye condition that occurs when blood flow to the optic nerve is suddenly reduced or blocked. It's also called an 'eye stroke'. The exact cause of NAION remains unclear and there are no current treatments available. People with diabetes are at increased risk of developing NAION. Unlike other eye conditions that develop gradually, NAION causes a sudden, painless loss of vision. Patients typically notice the condition when they wake up and discover they've lost vision in one eye. Vision tends to worsen over a couple of weeks and slowly stabilises. Recovery of vision is variable, but around 70 per cent of people do not experience improvement in their vision. What has previous research shown? A previous study from 2024 found participants prescribed semaglutide for diabetes were four times more likely to develop NAION. For those taking it for weight loss, the risk was almost eight times higher. In June, the European Medicines Agency concluded NAION represented a 'very rare' side effect of semaglutide medications: a one in 10,000 chance. In a first for medicines regulators, the agency now requires product labels to include NAION as a documented risk. However the recent studies suggest the risks may be lower than we first thought. In addition to NAION, there is also evidence to suggest GLP-1 drugs can worsen diabetic eye disease, also known as diabetic retinopathy. This occurs when high blood sugar levels damage the small blood vessels in the retina, which can lead to vision loss. It may sound counter-intuitive, but rapid blood sugar reductions can also destabilise the fragile blood vessels in the retina and lead to bleeding. What do the new studies say? Two newly published studies investigated people with type 2 diabetes living in the United States over two years. The studies looked at the medical records of 159,000 to 185,000 people. One study found semaglutide or tirzepatide was associated with a more modest risk of developing NAION than previously thought. Of 159,000 people with type 2 diabetes who were taking these drugs, 35 people (0.04 per cent) developed NAION, compared with 19 patients (0.02 per cent) in the comparison group. The researchers also found an increased risk of developing 'other optic nerve disorders'. However, it's unclear what kind of optic nerve disorders this includes, as the medical record codes used didn't specify. Counter to this, the second study did not find an increased risk of NAION among those taking GLP-1 drugs. However, the researchers found a small increase in the number of people developing diabetic retinopathy in those prescribed GLP-1 drugs. But overall, participants on GLP-1 drugs experienced fewer sight-threatening complications related to their diabetic retinopathy and required less invasive eye treatments compared to the group taking other diabetes medications. Further studies are still needed to understand how GLP-1 drugs can lead to eye complications. A current, five-year clinical trial is studying the long-term effects of semaglutides and diabetic eye disease in 1,500 people, which should tell us more about the ocular risks in the future. What does this mean for people taking GLP-1 drugs? NAION is a serious condition. But we need to strike a balance between these (and other) risks and the benefits of GLP-1 medications in diabetes care, obesity treatment, reducing heart attack risks and extending lives. The key lies in informed decision-making and identifying different levels of risk. People with multiple NAION risk factors – such as sleep apnoea, high blood pressure and diabetes – should undergo careful consideration with their treating doctor before starting these medications. 'Crowded' optic nerve heads are also a risk factor for NAION. This is an anatomical feature where blood vessels at the optic nerve head are tightly packed together. People with crowded optic nerve heads should also undergo careful consideration before starting GLP-1 medications. Although NAION can strike without warning, regular comprehensive eye examinations with your optometrist or ophthalmologist still serve important purposes. They can detect other drug-related eye problems, including worsening diabetic retinopathy, and can identify patients with crowded optic nerve heads. It's also important to tell them if you are taking GLP-1 medications so they can keep a close watch on your eye health. Emerging research also suggests that improving your heart health might help reduce risks of developing NAION. This includes proper management of high blood pressure, diabetes and cholesterol – all conditions that compromise the small blood vessels feeding the optic nerve. Studies also show patients with heart conditions who better adhere to their medication prescriptions have lower risks of NAION than those who don't. Doctors should discuss NAION risks during prescribing decisions and work with eye care providers to monitor regularly for diabetic eye disease. Patients need clear instructions to seek immediate medical attention for sudden vision loss and the need for regular eye examinations. Aggressive treatment of sleep apnoea and other heart conditions may also help reduce NAION risks. But for now, there remains an ongoing need for more research to understand how GLP-1 medications can affect the eye.
News18
4 hours ago
- News18
What It Takes to Build an FDA-Approved Oncology Plant in India
The strategic, operational, and compliance playbook behind India's growing footprint in regulated cancer drug markets. India's pharmaceutical industry has earned its place as the world's largest supplier of generic medicines, with over 650 manufacturing facilities approved by the US FDA. This number positions India as the global custodian in generics. While this statistic is often cited to highlight scale, a more telling sign of maturity is the rising number of oncology plants built in India, not just to serve domestic markets but to meet the stringent regulatory standards of the US and EU. Among all drug categories, oncology manufacturing demands the most rigorous quality controls, cleanroom architecture, and data integrity systems. Building such a facility isn't a matter of scaling up what already exists. It's a fundamental shift in how a company thinks, plans, executes, and sustains compliance. The difference begins with the product itself. Oncology drugs, especially those based on highly potent APIs, cytotoxics, or monoclonal antibodies, require full containment, sophisticated air-handling systems, and precise zone separation. Even minor lapses in cross-contamination or validation can result in patient harm. Unlike standard oral generics, oncology formulations often involve sterile injectables, lyophilised powders, or targeted biologics. Each step in the process, from material handling to packaging, must be validated against international GMP standards. They must undergo installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) validation and continuous environmental monitoring. These aren't mere upgrades to existing facilities. They are entirely new ecosystems built from the ground up. The journey of getting FDA Approval begins long before a brick is laid. The process begins with site selection. This plays a critical role, especially when waste handling and zoning compliance for hazardous materials are involved. Pharma hubs in Gujarat, Baddi, Telangana, and Maharashtra offer infrastructural advantages, but even here, environmental clearance, utility design, and HVAC zoning take months to finalise. The regulatory approvals run in parallel. Companies need to secure a state manufacturing license, followed by CDSCO approval and eventually, US FDA registration. In parallel, the design and construction teams work closely with quality and validation teams to establish protocols for cleanroom classification, air change rates, and water-for-injection (WFI) systems. Once construction is complete, validation begins with processes like IQ, OQ and PQ being run across all systems from HVAC to filling lines, and every deviation is documented and closed. This phase alone can stretch over six to nine months. In total, it can take two to three years from planning to inspection. This integrated effort demands not just technical competence but cultural alignment. Companies that invest early in staff training, data integrity systems, and audit simulations are typically better prepared for FDA scrutiny. Those that delay often face the issuance of Form 483, an inspectional observation report listing any conditions that may violate the Food, Drug, and Cosmetic Act. These findings range from incomplete batch records to deficiencies in aseptic processing and signal gaps in quality systems. As global inspections ramped up in recent times, foreign FDA drug inspections more than doubled from 130 in FY2021 to 262 in FY2022, where OAI outcomes have steadily declined, reflecting better inspection readiness and improved documentation culture. The returns, however, justify the effort. Once approved, the facility gives huge access to the US and European markets, where oncology drugs represent one of the fastest-growing therapeutic segments. Mr. Vishwa Savla, the Managing Director and CEO of Pinnacle Life Science, which got US FDA Approval last year, said in this context, 'We knew from the beginning that if we got this right, it would change the trajectory of our company. Of course, it's a high-stakes investment, but the payoff is clear. My team was sure that this would take time, but we knew that we were building our capability for a lifetime once the facility was operational. And it's needless to emphasise that if you're serious about oncology, you have to build to FDA standards. There's no shortcut to that. The oncology pipeline demands long-term thinking, and FDA approval gave us a foothold in markets where both quality and trust are non-negotiable." Ultimately, building an FDA‑licensed oncology plant in India demands capital, time, technical rigour, and cultural commitment. But with global oncology spending expected to exceed USD 375 billion by 2027, Indian companies that invest in compliance today are positioning themselves for long-term value not just commercially, but in terms of credibility and global impact. (Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: August 12, 2025, 12:00 IST News agency-feeds What It Takes to Build an FDA-Approved Oncology Plant in India Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
